Q2 2025 · 13F-HR
Birchview Capital, LPholdings as filed
Filed 2025-08-14 · accession 0001618205-25-000009
$100.7M
Reported value
71
Positions
2025-06-30
Period end
The Brief · Birchview Capital, LP · Q2 2025
AI · grounded in 13F
Birchview Capital, LP established a new position in Bristol-Myers Squibb Co BMY valued at $14.97M. The fund also initiated a new stake in KLA Corporation KLAC for $14.20M. Additional new positions include Corcept Therapeutics Inc CORT at $4.93M and Ovintiv Inc OVV at $4.09M. The fund ended the period with 71 positions and total AUM of $100.70M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $15.0M | 14.9% | 323,358 | Common | SOLE |
| 482480100 | KLAC | KLA CORPORATION | $14.2M | 14.1% | 15,848 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $4.9M | 4.90% | 67,200 | Common | SOLE |
| 69047Q102 | OVV | OVINTIV INC | $4.1M | 4.06% | 107,500 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $4.1M | 4.02% | 187,800 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $3.9M | 3.86% | 30,940 | Common | SOLE |
| 71944F106 | PHR | PHREESIA INC | $3.3M | 3.24% | 114,700 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $2.7M | 2.72% | 451,019 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $2.7M | 2.63% | 48,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $2.4M | 2.37% | 210,000 | Common | SOLE |
| 05479K106 | ELUT | ELUTIA INC | $2.3M | 2.28% | 1,159,059 | Common | SOLE |
| 14843C105 | CSTL | CASTLE BIOSCIENCES INC | $2.3M | 2.24% | 110,600 | Common | SOLE |
| 74838J101 | QDELUSD | QUIDELORTHO CORP | $2.1M | 2.08% | 72,548 | Common | SOLE |
| 26884L109 | EQT | EQT CORPORATION | $2.0M | 2.01% | 34,619 | Common | SOLE |
| 415858109 | HROW | HARROW HEALTH INC | $1.8M | 1.82% | 60,000 | Common | SOLE |
| G6674U108 | NVCR | NOVOCURE LTD | $1.8M | 1.79% | 101,000 | Common | SOLE |
| 05463X106 | AXGN | AXOGEN INC | $1.7M | 1.73% | 161,000 | Common | SOLE |
| 09075X108 | BDSX | BIODESIX INC | $1.6M | 1.61% | 5,736,113 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $1.5M | 1.51% | 103,000 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $1.5M | 1.45% | 310,930 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $1.4M | 1.42% | 50,000 | Common | SOLE |
| 574795100 | MASI | MASIMO CORP | $1.4M | 1.38% | 8,280 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $1.4M | 1.37% | 98,697 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $1.2M | 1.21% | 4,250 | Common | SOLE |
| 256086109 | DCGO | DOCGO INC | $1.2M | 1.19% | 764,062 | Common | SOLE |
| 89455T109 | TMCI | TREACE MEDICAL CONCEPTS INC | $1.0M | 1.03% | 176,947 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $870,600 | 0.86% | 178,768 | Common | SOLE |
| G5269C101 | — | KINIKSA PHARMACEUTICALS LTD | $830,100 | 0.82% | 30,000 | Common | SOLE |
| 35671D857 | FCX | FREEPORT-MCMORAN CL-B | $781,737 | 0.78% | 18,033 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $757,435 | 0.75% | 67,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $746,640 | 0.74% | 36,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $694,880 | 0.69% | 16,000 | Common | SOLE |
| 690145107 | OMGBP | OUTSET MEDICAL INC | $664,359 | 0.66% | 34,584 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $657,300 | 0.65% | 21,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $654,480 | 0.65% | 18,000 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $626,340 | 0.62% | 6,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $570,840 | 0.57% | 134,000 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HOLDING CORP | $566,720 | 0.56% | 16,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $562,800 | 0.56% | 60,000 | Common | SOLE |
| 68752L100 | KIDS | ORTHOPEDIATRICS CORP | $558,480 | 0.55% | 26,000 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $558,000 | 0.55% | 60,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $550,200 | 0.55% | 70,000 | Common | SOLE |
| 40637H109 | HALO | HALOZYME THERAPEUTICS INC | $520,200 | 0.52% | 10,000 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF INC | $496,000 | 0.49% | 400,000 | Common | SOLE |
| 45720N103 | INBX | INHIBRX BIOSCIENCES INC | $458,210 | 0.46% | 32,110 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $377,600 | 0.37% | 8,000 | Common | SOLE |
| 02081G201 | ATEC | ALPHATEC HOLDINGS INC | $366,300 | 0.36% | 33,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $358,400 | 0.36% | 40,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $346,086 | 0.34% | 2,700 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $330,400 | 0.33% | 10,000 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $303,600 | 0.30% | 60,000 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $300,700 | 0.30% | 155,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $287,200 | 0.29% | 40,000 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $261,950 | 0.26% | 40,300 | Common | SOLE |
| 88025U109 | TXG | 10X GENOMICS INC | $254,760 | 0.25% | 22,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $242,340 | 0.24% | 14,000 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $239,750 | 0.24% | 25,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $215,900 | 0.21% | 5,000 | Common | SOLE |
| 641288105 | NPCE | NEUROPACE INC | $183,164 | 0.18% | 16,442 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $169,956 | 0.17% | 138,176 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $160,440 | 0.16% | 28,000 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $159,885 | 0.16% | 16,500 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $150,600 | 0.15% | 20,000 | Common | SOLE |
| 48576U106 | KPTIEUR | KARYOPHARM THERAPEUTICS INC | $120,615 | 0.12% | 27,985 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $87,108 | 0.09% | 280,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $61,632 | 0.06% | 28,800 | Common | SOLE |
| N44821101 | IFRX | INFLARX NV | $39,500 | 0.04% | 50,000 | Common | SOLE |
| 03835L405 | APVO | APTEVO THERAPEUTICS INC | $30,500 | 0.03% | 10,000 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $30,000 | 0.03% | 10,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $19,720 | 0.02% | 17,000 | Common | SOLE |
| 00430H102 | — | ACCELERATE DIAGNOSTICS INC | $2,082 | 0.00% | 325,239 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.